> top > docs > PMC:7558914 > spans > 13525-14528 > annotations

PMC:7558914 / 13525-14528 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T5 69-76 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T6 69-76 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T7 116-123 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T8 116-123 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T9 172-179 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T10 172-179 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T11 293-300 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T12 293-300 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T13 533-540 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T14 533-540 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T15 699-706 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T16 699-706 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T17 783-790 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T18 783-790 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T19 946-953 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T20 946-953 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
330 69-76 Chemical denotes heparin MESH:D006493
331 116-123 Chemical denotes heparin MESH:D006493
332 172-179 Chemical denotes heparin MESH:D006493
333 293-300 Chemical denotes heparin MESH:D006493
334 533-540 Chemical denotes heparin MESH:D006493
335 699-706 Chemical denotes heparin MESH:D006493
336 783-790 Chemical denotes heparin MESH:D006493
337 946-953 Chemical denotes heparin MESH:D006493
338 219-227 Disease denotes COVID-19 MESH:C000657245
339 343-353 Disease denotes thrombosis MESH:D013927
340 362-370 Disease denotes COVID-19 MESH:C000657245
341 424-446 Disease denotes venous thromboembolism MESH:D054556
342 450-479 Disease denotes acute ischemic artery disease MESH:D014715
343 732-754 Disease denotes venous thromboembolism MESH:D054556

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T24 388-413 Phenotype denotes cytokine release syndrome http://purl.obolibrary.org/obo/HP_0033041
T25 431-446 Phenotype denotes thromboembolism http://purl.obolibrary.org/obo/HP_0001907
T26 739-754 Phenotype denotes thromboembolism http://purl.obolibrary.org/obo/HP_0001907

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T93 0-203 Sentence denotes All protocols included anticoagulant treatment (low-molecular-weight heparin as the first option and unfractionated heparin as an alternative) and recommended prophylactic heparin during hospitalization.
T94 204-505 Sentence denotes In 8 of the 15 COVID-19 protocols (53.3%), the dose of prophylactic low-molecular-weight heparin was increased if there was a high risk of thrombosis (severe COVID-19 with evidence of cytokine release syndrome, previous venous thromboembolism or acute ischemic artery disease, or D-dimer >3000 ng/mL).
T95 506-663 Sentence denotes In five protocols (33.3%), heparin was increased to therapeutic doses if the condition was critical or if there was a progressive increase in D-dimer levels.
T96 664-755 Sentence denotes All protocols included therapeutic heparin if there was evidence of venous thromboembolism.
T97 756-930 Sentence denotes At discharge, prophylactic heparin was recommended if D-dimer >1500-3000 ng/dL for 7 days or during the time of the expected severe immobilization in seven protocols (46.6%).
T98 931-1003 Sentence denotes Adjustments of heparin doses were indicated in the respective protocols.